Kura Oncology NASDAQ: KURA reported $5.8 million in first-quarter net product revenue from KOMZIFTI, its first commercial product, and said the launch is showing early signs of physician uptake, broad payer coverage and use in combination regimens, according to management’s earnings call for the first quarter of 2026.President and Chief Executive Officer Dr. Troy Wilson described the company as being “at an inflection point,” citing the commercial launch, phase III programs that he said are ahead of plan an ...

Kura Oncology (KURA) came out with a quarterly loss of $0.83 per share versus the Zacks Consensus Estimate of a loss of $0.88. This compares to a loss of $0.66 per share a year ago. These figures are adjusted for non- recurring items. This quarterly report represents an earnings surprise of +5.33%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.72 per share when it actually produced a loss of $0.92, delivering a surprise of -27.78%. Over the last four quarters, th ...

Kura Oncology (NasdaqGS:KURA) Q1 2026 Earnings call May 12, 2026 04:30 PM ET Conference Call Participants Dan Bronder - Analyst Daniel Brims - Analyst David Dai - Analyst Etzer Darout - Analyst Jonathan Chang - Analyst Nabil Belhadj - Analyst Peter Green - Analyst Philip Nadeau - Analyst Reni Benjamin - Analyst Salim Syed - Analyst Operator Good day, everyone. My name is Layla, and I will be your conference operator today. At this time, I would like to welcome you to the Kura Oncology First Quarter 2026 fin ...

Kura Oncology (NasdaqGS:KURA) Q1 2026 Earnings call May 12, 2026 04:30 PM ET Company Participants Brian Powl - Chief Commercial Officer Greg Mann - SVP of Investor Relations and Corporate Affairs Mollie Leoni - Chief Medical Officer Tom Doyle - SVP of Finance and Accounting Troy Wilson - President and CEO Conference Call Participants Dan Bronder - Analyst Daniel Brims - Analyst David Dai - Analyst Etzer Darout - Analyst Jonathan Chang - Analyst Nabil Belhadj - Analyst Peter Green - Analyst Philip Nadeau - A ...

Kura Oncology (NasdaqGS:KURA) Q1 2026 Earnings call May 12, 2026 04:30 PM ET Speaker9Good day, everyone. My name is Layla, and I will be your conference operator today. At this time, I would like to welcome you to the Kura Oncology First Quarter 2026 financial results earnings call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, and if you have joined via the w ...

– $5.8 million in KOMZIFTI™ (ziftomenib) net product revenue in first full quarter of commercialization – – Multiple 2026 data readouts expected to support ziftomenib as a broadly combinable backbone across AML – – $580.8 million in cash, cash equivalents and short-term investments, plus $180 million in anticipated collaboration payments, expected to support advancement of ziftomenib AML program through first topline KOMET-017 Phase 3 results – – Management to host webcast and conference call today at 4:30 ...

– Durable responses with median duration of CRc not reached in NPM1-m patients at ~15 months median follow-up – – Phase 3 KOMET-017 trial currently enrolling with potential for accelerated FDA review in 2028 – – Oral presentation to feature 99-patient dataset with extended follow-up in newly diagnosed NPM1-m or KMT2A-r AML – – High CRc rates (90–96%) with deep MRD negativity (> 80%) across both subtypes – – Virtual Kura investor call on June 3 at 8:00 a.m. ET – SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Ku ...